Announcement on daily connected transactions of subsidiaries
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2018-006
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司日常关联交易的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、日常关联交易基本情况
(一)日常关联交易基本情况和履行的审议程序
根据公司经营需要,2018年本公司控股子公司浙江尖峰药业有限公司(以下简称“尖峰药业”)将向关联方陕西天士力医药有限公司(以下简称“陕西天士力”)出售商品;尖峰药业的控股子公司金华市医药有限公司(以下简称“金华医药”)将向关联方天津天士力医药商业有限公司(以下简称“天士力医药”)采购商品;本公司控股子公司浙江尖峰健康科技有限公司(以下简称“尖峰健康”)将向关联方天津天士力现代中药资源有限公司(以下简称“天士力中药”)出售商品。
预计2018年度,上述日常关联交易合计发生额度在本公司2017年底经审计净资产的0.5%到5%之间(不超过13136.59万元),根据上海证券交易《股票上市规则》及公司《章程》的规定,该关联交易事项需提交董事会审议,但不需提交股东大会审议。
2018年4月20日,公司召开了第十届董事会第三次会议,公司全体九名董事亲自参加了会议,关联董事蒋晓萌先生、杜自弘先生回避了该议案的表决,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。经审议与表决,董事会以7票同意、0票反对、0票弃权审议通过了《关于子公司日常关联交易的议案》。
公司独立董事事前对该事项进行了审议,同意将该议案提交给公司第十届董事会第三次会议审议;对董事会通过该议案发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
(二)预计日常关联交易内容和金额 单位:万元
|
交易内容 |
关联人 |
定价原则 |
2018年预计金额 |
2018年已发生额 |
2017年发生额(不含税) |
占同类交易金额的比例% |
|
采购商品 |
天士力医药 |
以医疗机构中标价为基准协商确定 |
1736.47 |
6.11 |
416.17 |
0.26 |
|
出售商品 |
天士力中药 |
招标确定 |
871.80 |
180.60 |
545.02 |
0.007 |
|
出售商品 |
陕西天士力 |
以医疗机构中标价为基准协商确定 |
60.00 |
16.56 |
21.23 |
0.19 |
|
合计 |
|
|
2668.27 |
203.27 |
982.42 |
0.457 |
二、关联方介绍和关联关系
(一)关联方的基本情况。
1、天士力医药:该公司成立于2011年08月,公司住所为天津自贸试验区(东疆保税港区)亚洲路6865号金融贸易中心北区1-1-2303,1-1-2304室,法定代表人闫凯境,该公司注册资本金为1190.00 万元。该公司主营业务范围为:中成药、化学原料药及其制剂、抗生素原料药及其制剂、生化药品、生物制品、中药饮片、中药材、第三医疗器械批发、包装材料及容器(医用除外)、塑料制品、模具、塑料原料、化妆品、健身器材、文化用品、保洁用品、日用品、日用百货、消毒用品、卫生洗液批发兼零售;烟零售;保健食品、第一、二类医疗器械、食品销售(取得许可证后方可经营);计算机软硬件技术开发、转让、咨询服务;国内货物运输代理服务;从事国家法律法规允许经营的进出口业务。截至2017 年12月31 日该公司总资产327,437.77 万元,净资产22,827.90 万元,2017 年实现净利润13,355.54 万元。
2、天士力中药:成立于2003年3月,住所为天津市北辰区科技园区,法定代表人朱永宏,注册资本33470.11万元,经营范围为:中药数字仪器、制药设备及技术的开发、生产、销售;中药数字化检测分析及相关技术咨询服务;中药材、日用化学品提取物的加工及销售(食品、药品及化学危险品、易制毒品除外);中草药采购;流浸膏剂;原料药(穿心莲内酯)生产;进出口业务;化妆品批发兼零售。(依法须经批准的项目,经相关部门批准后方可开展经营活动)。截至2017年12月31日,该公司总资产88,680.74万元,净资产68,389.69万元,2017年实现净利润10,301.98万元。
3、陕西天士力:成立于1996年7月,住所为陕西省西咸新区沣东新城三桥镇建章路188号,法定代表人闫凯境,注册资本7000.00万元,经营范围为:中成药、中药材、中药饮片、化学原料药、化学药制剂、抗生素制剂、生化药品;生物制品(除疫苗)、第二类精神药品、蛋白同化制剂、肽类激素的批发;第一类医疗器械、第二类医疗器械、第三类医疗器械的批发经营;医用消毒产品、保健食品的批发;预包装食品、特殊医学用途配方食品、玻璃仪器的批发兼零售;乳制品(含婴幼儿配方乳粉)、化妆品、劳保用品、日用百货、农副产品的销售;商品信息、医药技术信息咨询(金融、证券、期货、基金投资咨询等专控除外);仓储及运输(危险品除外)、会议及展览服务、咨询。(依法须经批准的项目,经相关部门批准后方可开展经营活动)。截至2017年12月31日,该公司资产总额108,815万元,负债总额101,362 万元,2017年度实现净利润2,344万元。
(二)与上市公司的关联关系
天士力医药、天士力中药、陕西天士力都是本公司联营企业天士力控股集团有限公司(以下简称“天士力集团”)的下属子公司,本公司持有天士力集团20.76%的股权,且本公司董事蒋晓萌先生、杜自弘先生兼任天士力集团的董事,所以本公司与天士力医药、天士力中药、陕西天士力存在关联关系。
(三)2017年,公司与上述关联方之间发生的关联交易金额为982.42万元(不含税),占同类交易金额的比例很小,不会影响公司独立性。关联交易的执行情况良好,没有发生纠纷。
三、关联交易主要内容和定价政策
(一)金华医药公司拟在本年度继续向天士力医药采购药品进行销售,本项关联交易的主要内容如下:
1.交易标的:复方丹参滴丸、养血清脑颗粒等。
2.交易价格:以医疗机构中标价为基准协商确定。
3.结算方式:先付款后发货。
(二)尖峰健康拟在本年度继续向天士力现代中药出售商品,本项关联交易的主要内容如下:
1.交易标的:延胡索,生半夏。
2.交易价格:招标确定。
3.结算方式:货到检验合格收到发票后两个月内支付。
(三)尖峰药业拟在本年度继续向陕西天士力销售商品,本项关联交易的主要内容如下:
1.交易标的:注射用盐酸头孢甲肟
2.交易价格:以医疗机构中标价为基准协商确定
3.结算方式:款到发货
四、关联交易目的和对上市公司的影响
上述日常关联交易是基于双方的产品优势和销售、采购的网络优势基础上达成的,有利于各方扩大业务,提升营销能力,增加销售收入。同时,天士力医药、天士力中药、陕西天士力都是本公司联营企业的下属子公司,该公司的收入增加、效益提升也有利于本公司的业绩增长。
上述交易遵守“公平、公正、公开”的市场交易原则,以中标价为基础协商确定交易价格,交易金额占各自销售收入的比例较小,不会影响公司独立性,不会对公司的财务状况、经营成果产生不利影响,不会损害本公司或中小股东的利益。
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一八年四月二十四日
More information
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-30
Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Just one year after it was identified as a national intellectual property advantage enterprise in 2016, "Zhejiang Jianfeng Pharmaceutical Co., Ltd." appeared in the list of national intellectual property demonstration enterprises in 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City. On December 12, the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017. After the enterprise declaration, the recommendation of the provincial and municipal bureaus, the review of the national bureau, and the public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as only 15 national intellectual property demonstration enterprises. With the continuous development of enterprises in recent years, Jianfeng Pharmaceutical has set up a special working organization to cultivate and improve the intellectual property ability from the aspects of strategic management, creation, operation and protection of intellectual property rights. It has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System, and timely according to the policy, the current situation of the enterprise to revise, in order to ensure the compliance and effectiveness of the operation of the system. In 2012 and 2013, Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province; in 2013, it won the third prize of Jinhua Patent Implementation Award; in 2016, it passed the certification of intellectual property management system and was identified as a national intellectual property advantage enterprise. Currently, Peak Pharmaceuticals has
2020
07-31
Jianfeng Pharmaceutical Approved to Set up Provincial Research Institute
A few days ago, the relevant departments of Zhejiang Province approved the establishment of the provincial research institute of the peak pharmaceutical company. This is another honor won by Jianfeng Pharmaceutical in the field of independent research and development and scientific and technological innovation after the national postdoctoral research workstation and Zhejiang academician expert workstation. The provincial enterprise research institute is a high-level R & D institution led by the Provincial Department of Science and Technology, jointly recognized by the Provincial Economic and Information Commission and the Provincial Development and Reform Commission. As an important part of the national technological innovation system, the Enterprise Research Institute is the core force of the innovation-driven development of Jianfeng Pharmaceutical, which reflects the ability of Jianfeng Pharmaceutical to set up higher-level and higher-level R & D institutions on its own. the ability to gather and integrate innovation elements, organize scientific and technological innovation, support the sustainable development of enterprises, and lead the technological progress of the industry. As a pharmaceutical enterprise, scientific and technological innovation is the eternal theme of enterprise development, and talent is the key to scientific and technological innovation. Over the years, Jianfeng Pharmaceutical has not only focused on cultivating its own scientific research talents, but also established close cooperative relations with well-known universities and scientific research institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan Antibiotic Industry Research Institute, and also focused on introducing top think tanks. In 2011, Professor Liu Jiajian and his team from Sichuan Institute of Antibiotic Industry were introduced, focusing on the technical research of key intermediates of methoxy cephalosporin. In 2013, Professor Shan Weiguang and his scientific research team from Zhejiang University of Technology were introduced to carry out research on preparation technology. In 2015, Professor Wang Guangji, academician of the Chinese Academy of Engineering, was hired as the chief scientist to organize the research on the anti-drug resistance mechanism of national class I new drugs by intracellular pharmacokinetics. In 2017 with Shanghai antibody
2020
07-31
On November 16, the company held the first extraordinary general meeting of shareholders in 2017, which deliberated and passed the proposal on the expiration of the term of the board of directors and the proposal on the expiration of the term of the board of supervisors, and elected a new board of directors and the board of supervisors. The meeting used a combination of on-site registered voting and online voting to vote on director candidates one by one, and elected Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Conyun, Sun Hongbin, and Shi Ximin as the company's tenth board of directors. Directors, of which Huang Conyun, Sun Hongbin, and Shi Ximin are independent directors. The meeting used a combination of on-site registered voting and online voting to vote on supervisor candidates one by one, and elected Chen Tianci, Lu Ruimei, and Shi Fu as supervisors of the company's ninth board of supervisors. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors. On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors. Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin were elected as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng was the chairman of the Strategy Committee. Shi Ximin, Huang Conyun and Jiang Xiaomeng were elected as members of the audit committee of the 10th board of directors, and Shi Ximin was the chairman. Sun Hongbin, Huang Conyun and Jiang Xiaomeng were elected as members of the nomination committee of the 10th board of directors, and Sun Hongbin was the chairman. Huang Cong Yun, Shi Ximin and Du Zihong were elected as members of the remuneration and assessment committee of the 10th board of directors, and Huang Cong Yun was the chairman. The board of directors appointed Yu Jianhong as the general manager of the company and appointed Huang Jinlong.
2020
07-31
Peak natural products pollution control results by the industry attention
As a leader in China's plant extracts industry, Tianjin Jianfeng Natural Products Company has achieved fruitful results in technological innovation. On October 26 and 27, at the 2017 Forum on improving the international competitiveness of China's plant extract industry held in Handan City, Hebei Province, Liu Dan, general manager of the company, delivered a speech entitled "prevention and control of water pollution in the field of plant extraction", introducing the successful experience of sewage treatment in the past five years, which was widely concerned by the participants. In recent years, environmental protection and ecology have become hot words for the development of enterprises and society. Due to the particularity of the plant extraction industry, pollution control in this industry has different characteristics and requirements from ordinary production enterprises. For example, sewage presents higher chroma, extremely low PH value, more suspended solids, high salinity, high concentration of COD, and different sewage water quality of different products. As the earliest enterprise producing opc grape seed extract in China, Natural Products Company has always attached great importance to the pollution control of plant extraction. For example, in the sewage treatment upgrading project implemented in 2016, ozone oxidation and biochemical methods were adopted to remove the remaining organic pollutants, increasing the sewage treatment capacity from 200 cubic meters per day to 500 cubic meters. The latest anaerobic sewage treatment technology is adopted, the COD emission value of the outlet is reduced to 60 mg per liter, which is far lower than the national first-class emission standard of 100 mg per liter. The new system adopts advanced oxidation reaction tower, ozonation method, field energy reactor and sludge adsorption reflux technology, which can quickly and efficiently treat organic pollutants with strong chemical stability without adding any chemicals.
2020
07-31